Prabhani Atukorale to Cell Line, Tumor
This is a "connection" page, showing publications Prabhani Atukorale has written about Cell Line, Tumor.
Connection Strength
0.292
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
Score: 0.177
-
Parikh CN, DeMarco KD, Bhalerao N, Giwa HK, Kane GI, Dinnell RW, Ma B, Mori H, Brassil ML, Murphy KC, Zhao Z, Johnson C, Ramani S, Zhou L, Chibaya L, Qiao Y, Hu K, Zhu LJ, Lewis BC, Xue W, Pitarresi JR, Atukorale PU, Ruscetti M. Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer. Nat Commun. 2026 Jun 19; 17(1).
Score: 0.044
-
Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdhury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU, Ruscetti M. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024 08 28; 16(762):eadj9366.
Score: 0.039
-
Covarrubias G, Moon TJ, Loutrianakis G, Sims HM, Umapathy MP, Lorkowski ME, Bielecki PA, Wiese ML, Atukorale PU, Karathanasis E. Comparison of the uptake of untargeted and targeted immunostimulatory nanoparticles by immune cells in the microenvironment of metastatic breast cancer. J Mater Chem B. 2022 01 05; 10(2):224-235.
Score: 0.032